|
This complaint was reopened in reference to (b)(4).Manufacturing site evaluation: manufacturing and quality control data the progav¿ was manufactured by a qualified employee in june 2015.Deviations during assembly did not occur.The valve was sterilized by miethke and released for shipment after final inspection.The progav¿ has a normal pressure range of 0 to 20 cmh2o.The valve was inspected as article fv785t.All parameters have been inspected and approved during the manufacturing process.All parameters have been assessed as meeting specification.Device examination: the valve was received submersed in an unidentified liquid in the provided returnkit.Visual inspection: no significant deformations or damage to the valve were detected during the visual inspection.Permeability test: a permeability test has shown that the valve had a blockage.Adjustment test: the progav¿ was tested and was adjustable to all specified pressures.Braking force and brake function test: the brake functionality test has shown that the brake function was fully operational and the braking force was within given tolerances.Result first, a visual inspection of the progav¿ was performed.No significant deformations or damage to the valve were detected during the visual inspection.Next, the permeability, adjustability, as well as the brake functionally and brake force, of the valve were tested.The valve was not permeable, but met all other specifications.To ensure that the prosa¿ valve had not led to the suspected blockage, the prosa¿ was also examined.A visual examination identified a dent in the housing.The measurement of the plane-parallelism confirmed the presence of the deformation.Finally, the valve was dismantled.A build-up of a substance (likely protein) was observed inside the valve.Based on the investigation, the claim of valve occlusion was confirmed.This was likely due to the deposits observed inside the valve.As described in scientific literature, the problem encountered is one of the known, inevitable risks of hydrocephalus (hc)-therapy by shunt implants.Manufacturing defects at the time of release have been excluded.The valve met all specifications of the final inspection when released from christoph miethke (b)(4).No further regulatory actions are required.
|